OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell (OTCBB:ISCO - News), www.internationalstemcell.com, announced today that it will be providing corneal epithelial cells, derived from its Parthenogenetic stem cells and human keratinocytes (a type of skin cell), for use in Federal Drug Administration (FDA) clinical trials aimed at creating a tissue transplant technology to improve photorefractive keratectomy (PRK).
